National Hispanic Heritage Month takes place from September 15 to October 15. We would like to honor this month by featuring some resources (from PRIM&R and from other organizations) that highlight the importance of the inclusion of the Latinx community in clinical research. Read more
For research oversight committees, there is a certain appeal to using casuistry as a method, which is why I think we often end up there, even if we start from a more abstract point like the Belmont principles. Casuistry is an intuitive, somewhat concrete way —at least as far as ethics goes— of thinking about problems. When it comes to philosophical instruction (and often limited time to engage in abstract thinking for its own sake), casuistry can provide a nice nexus point between the abstract principles and policies and the practical decisions being made. Read more
APPE RISEsm invites you to submit a proposal for its annual symposium that explores the definition, scope and impact of engagement among researchers, institutions, communities and the public, with a view to foster discussions about the complex nature of engagement. Read more
As many of us know, conflicts of interest are becoming ever more complex and increasing as various translational activities are encouraged. In many cases, our transitions to remote work and virtual platforms for information sharing are driving this complexity. Read more
Research noncompliance occurs when researchers (intentionally or unintentionally) fail to comply with established regulations, policies, and/or committee-approved research protocols. Noncompliance comes in many forms. It is study-specific and not always identified by IRBs and IACUCs in the same manner. Some instances of noncompliance may be discovered through post-approval monitoring activities, while others come to the committees via whistleblowers, or reports submitted by the researchers themselves. Whatever the case, committees must decide what happens after noncompliance has been identified. Read more
This month's research ethics roundup covers scientists' problems with ClinicalTrials.gov, thoughts from the inventor of CRISPR, the FDA's "Animal Rule," and so-called "parachute science." Read more
